Pipeline
At 858 Therapeutics, we are advancing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. Our programs are focused on important nodes in cancer biology, including DNA damage repair, innate immunity, and RNA epigenetics. We leverage our deep expertise in structure-based drug discovery and translational research to develop differentiated drug candidates.
Target | Indication | Discovery | Preclinical | IND-enabling | Clinical | Rights | ||||
---|---|---|---|---|---|---|---|---|---|---|
PARG | Solid tumors | Complete | Complete | In Progress | Incomplete | |||||
QPCT/L | Neurodegeneration | Complete | Complete | In Progress | Incomplete | |||||
METTL3 | Solid tumors | Complete | Complete | In Progress | Incomplete | |||||
ADAR1 | Solid tumors | Complete | In Progress | Incomplete | Incomplete |
Target:
PARG
Indication:
Solid tumors
Rights:
Target:
QPCT/L
Indication:
Neurodegeneration
Rights:
Target:
METTL3
Indication:
Solid tumors
Rights:
Target:
ADAR1
Indication:
Solid tumors
Rights:
To learn more about partnering or licensing opportunities, please contact bd@8five8tx.com